Co-administration of our major histocompatibility complex (MHC)-I and MHC-II-restricted neoantigens increases antigen-specific T cell responses and exhibits strong anti-cancer efficacy, significantly inducing antigen-specific CD8<sup>+</sup> T cell-immune responses. This evidence concerns the gene CD8A and cancer.